StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The firm has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. The firm’s 50-day moving average is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 52-week low of $1.22 and a 52-week high of $8.45.
Nabriva Therapeutics Company Profile
Read More
- Five stocks we like better than Nabriva Therapeutics
- How to Most Effectively Use the MarketBeat Earnings Screener
- MarketBeat Week in Review – 4/29 – 5/3
- How to Evaluate a Stock Before Buying
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Business Services Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.